Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
741 to 760 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Flexible endoscopic evaluation of swallowing in children with type 1 spinal muscular atrophy. | Eur Arch Otorhinolaryngol | 2023 | 36209319 | PubTator, text mining | PubMed |
| Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen. | Pediatr Pulmonol | 2023 | 36193036 | PubTator, text mining | PubMed |
| MRI correlates of motoneuron loss in SMA. | J Neurol | 2023 | 36180649 | PubTator, text mining | PubMed |
| Retrotransposon insertion as a novel mutational cause of spinal muscular atrophy. | Hum Genet | 2023 | 36138164 | PubTator, text mining | PubMed |
| Year in review 2021: Neuromuscular diseases. | Pediatr Pulmonol | 2023 | 36134670 | PubTator, text mining | PubMed |
| Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy. | Curr Gene Ther | 2023 | 36111754 | PubTator, text mining | PubMed |
| Nociceptive pain in adult patients with 5q-spinal muscular atrophy type 3: a cross-sectional clinical study. | J Neurol | 2023 | 36036285 | PubTator, text mining | PubMed |
| Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. | Eur J Neurol | 2023 | 35837793 | PubTator, text mining | PubMed |
| Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. | J Hum Genet | 2023 | 35691950 | PubTator, text mining | PubMed |
| Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. | Dev Med Child Neurol | 2023 | 35673937 | PubTator, text mining | PubMed |
| A meditation on accelerating the development of small molecule medicines targeting RNA. | Expert Opin Drug Discov | 2023 | 35658797 | PubTator, text mining | PubMed |
| Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. | Gene Ther | 2023 | 35606491 | PubTator, text mining | PubMed |
| Adeno-associated virus serotype 9 antibody titers in patients with SMA pre-screened for treatment with onasemnogene abeparvovec -routine care evidence. | Gene Ther | 2023 | 35474244 | PubTator, text mining | PubMed |
| Nephrotoxicity of marketed antisense oligonucleotide drugs. | Curr Opin Toxicol | 2022 | 37193356 | PubTator, text mining | PubMed |
| Carrier frequency of Spino-muscular atrophy in individuals of a reproductive age group from North India. | J Family Med Prim Care | 2022 | 36994015 | PubTator, text mining | PubMed |
| Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine. | Front Cell Dev Biol | 2022 | 36699015 | PubTator, text mining | PubMed |
| Cell-Free Fetal DNA and Non-Invasive Prenatal Diagnosis of Chromosomopathies and Pediatric Monogenic Diseases: A Critical Appraisal and Medicolegal Remarks. | J Pers Med | 2022 | 36675662 | PubTator, text mining | PubMed |
| Biomarkers and molecular mechanisms of Amyotrophic Lateral Sclerosis. | AIMS Neurosci | 2022 | 36660079 | PubTator, text mining | PubMed |
| Brief considerations on targeting RNA with small molecules. | Fac Rev | 2022 | 36644293 | PubTator, text mining | PubMed |
| Benefits of tailored disease management in improving tremor, white matter hyperintensities, and liver enzymes in a child with heterozygous X-linked ornithine transcarbamylase deficiency. | Mol Genet Metab Rep | 2022 | 36620387 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=38